Q-omics provides the consensus-scored ARID3C profile across patient tissues and cancer cell-line models. ARID3C expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ARID3C is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, ARID3C RNA expression shows 13,342 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KIRP, and TGCT as cancer lineages where ARID3C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARID3C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARID3C survival associations across molecular data types. ARID3C RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARID3C RNA expression–survival associations across cancer types. High ARID3C expression shows unfavorable associations in KIRC, KIRP, BLCA, MESO and UCEC, but favorable associations in ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ARID3C RNA expression.
This table summarizes ARID3C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for ARID3C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARID3C shows lower tumor expression in LIHC and higher tumor expression in KIRP, BLCA, KIRC, COAD and LUSC. The KIRP box plot shows higher ARID3C RNA expression in tumor versus normal tissue (log2 FC = +0.754, t-test p < 0.001).
This table shows molecular features associated with ARID3C in patient tissues and cancer cell lines. In patient samples, ARID3C shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ARID3C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SOFT_TISSUE.
